Health Canada consultation on reducing youth access and appeal of vaping products

https://policybase.cma.ca/link/policy14078

POLICY TYPE
Response to consultation

DATE
2019-05-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
         Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE 2018-12-04
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE
Response to consultation

DATE
2018-10-02

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol

https://policybase.cma.ca/link/policy13927

POLICY TYPE
Response to consultation

DATE
2018-08-14

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2018-07-18</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

HEALTH CANADA CONSULTATION ON RESTRICTION OF MARKETING AND ADVERTISING OF OPIOIDS

jun 14, 2018
Dear [Recipient],

The Canadian Medical Association (CMA) is pleased to have the opportunity to provide input on the proposed front-of-package labelling of cannabis products. We appreciate the opportunity to contribute to this important public health issue.

The CMA believes that any proposed front-of-package labelling should be based on sound scientific evidence and be consistent with the principles of good health promotion. Any new regulations should be transparent, evidence-based, and reflect the best available data on the health effects of cannabis.

The CMA also recommends that any proposed front-of-package labelling should be consistent with existing regulations for other products, such as alcohol and tobacco. This consistency will help consumers make informed decisions about their health and safety.

Sincerely,

[Your Name]
Canadian Medical Association
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products

https://policybase.cma.ca/link/policy13799

POLICY TYPE: Response to consultation
DATE: 2017-12-07
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image: CMA Submission: Excise Duty Framework for Cannabis Products]

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE: Response to consultation
DATE: 2017-11-7
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE   Response to consultation
DATE          2017-06-28
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Document
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation
DATE  2017-04-05
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

As of 2017:

Consultation on the renewal of Federal Tobacco Control Strategy

On behalf of the Canadian Medical Association (CMA), I am responding in your request for consultation on the renewal of the Federal Tobacco Control Strategy (FTCS) and on the implementation of the Framework Convention on Tobacco Control (FCTC).

We are pleased to submit this position paper on the renewal of the FTCS. The FCTC is a historic achievement in public health, as it is the first time governments have come together to address a major global health threat. It is a global movement that is generating renewed momentum to reduce tobacco use and its deadly consequences. Tobacco use remains a major global health threat, contributing to one in six deaths worldwide. Tobacco is the leading cause of preventable premature death and disease, particularly in low- and middle-income countries.

As the Summit suggests, a renewed strategy must go beyond the traditional approaches of increased tobacco control measures by focusing on the world’s future health security while offering strong assistance to low-income tobacco markets. The Summit called for increased tobacco control data, including comprehensive information on tobacco demand, availability, and use.

The CMA believes that smoking cessation in smoking rats, tobacco control remains a priority, and we continue to be supported by a sustained, well-funded tobacco strategy, strong regulation, and support from tobacco control, including a comprehensive

CMA Policybase - Canadian Medical Association
Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone

https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy1814

**POLICY TYPE**
Response to consultation

**DATE**
2016-01-20

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE  2015-06-08
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE Response to consultation
DATE 2014-08-26
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents